Looking for:
elocon_cream |
Mometasone Furoate 1mg/g Cream should not be used on wounds or on skin which is ulcerated. These preparations are not cost-effective in primary care and there may be a significant delay in obtaining such preparations. Doxepin cream can cause drowsiness that may affect skilled tasks and there may be a risk of sensitisation. Chronic corticosteroids therapy may interfere with the growth and development of children.
Mometasone Furoate 1mg/g Cream should be administered to nursing mothers only after careful consideration of the benefit/risk relationship. If treatment with higher doses or long term application is indicated, breast feeding should be discontinued. Long term continuous or inappropriate use of topical steroids can result in the development of rebound flares after stopping treatment . A severe form of rebound flare can develop which takes the form of a dermatitis with intense redness, stinging and burning that can spread beyond the initial treatment area. It is more likely to occur when delicate skin sites such as the face and flexures are treated. Should there be a reoccurrence of the condition within days to weeks after successful treatment a withdrawal reaction should be suspected.
Topical administration of corticosteroids to pregnant animals can cause abnormalities of foetal development including cleft palate and intra-uterine growth retardation. There are no adequate and well-controlled studies with Mometasone Furoate in pregnant women and therefore the risk of such effects to the human foetus is unknown. However as with all topically applied glucocorticoids, the possibility that foetal growth may be affected by glucocorticoid passage through the placental barrier should be considered.
In guinea pigs, mometasone was approximately twice as potent as betamethasone valerate in reducing m.ovalis-induced epidermal acanthosis (i.e. anti-psoriatic activity) after 14 applications. In the croton oil assay in mice, mometasone was equipotent to betamethasone valerate after single application and about 8 times as potent after five applications. If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application or to substitute a less potent steroid.
Patients applying a topical steroid to a large surface area or areas under occlusion should be evaluated periodically for evidence of HPA axis suppression. During pregnancy treatment with Mometasone Furoate should be performed only on the physician's order. Then however, the application on large body surface areas or over a prolonged period should be avoided.
Comments
Post a Comment